Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 Receptor Agonists and Kidney Protection
Eulalia Greco, Giuseppina Russo, Annalisa Giandalia, et al.
Medicina (2019) Vol. 55, Iss. 6, pp. 233-233
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Therapeutic peptides: current applications and future directions
Lei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 1155
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 93
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
Erin D. Michos, George L. Bakris, Helena W. Rodbard, et al.
American Journal of Preventive Cardiology (2023) Vol. 14, pp. 100502-100502
Open Access | Times Cited: 63
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
José Luis Górriz, María José Soler, Juan F. Navarro‐González, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 4, pp. 947-947
Open Access | Times Cited: 118
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
Diabetes Care (2020) Vol. 43, Iss. 11, pp. 2859-2869
Open Access | Times Cited: 105
Kaempferol in ameliorating diabetes-induced fibrosis and renal damage: An in vitro and in vivo study in diabetic nephropathy mice model
Dilip Kumar Sharma, Rakesh Kumar Tekade, Kiran Kalia
Phytomedicine (2020) Vol. 76, pp. 153235-153235
Closed Access | Times Cited: 99
New progress in drugs treatment of diabetic kidney disease
Junmin Wang, Hongjiao Xiang, Yifei Lü, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111918-111918
Open Access | Times Cited: 56
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
Khary Edwards, Xilong Li, Ildiko Lingvay
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 108, Iss. 4, pp. 920-930
Closed Access | Times Cited: 53
Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives
Yu Wang, Mingyue Jin, Chak Kwong Cheng, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 38
Autophagy and its therapeutic potential in diabetic nephropathy
Yu-Peng Han, Lijuan Liu, Jia-Lin Yan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 28
Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease
Weronika Frąk, Bartłomiej Dąbek, Marta Balcerczyk-Lis, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 687-687
Open Access | Times Cited: 11
Cardiovascular and Kidney Outcomes of Glucagon-Like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Nicole Felix, Mateus de Miranda Gauza, Vinicius Bittar, et al.
Cardiorenal Medicine (2025) Vol. 15, Iss. 1, pp. 98-107
Open Access | Times Cited: 1
ACUTE HYPERGLYCEMIA INDUCES PODOCYTE APOPTOSIS BY MONOCYTE TNF-α RELEASE, A PROCESS ATTENUATED BY VITAMIN D AND GLP-1 RECEPTOR AGONISTS
Rong M. Zhang, Jisu Oh, Burton M. Wice, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2025), pp. 106676-106676
Closed Access | Times Cited: 1
Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
Jui‐Yi Chen, Tsuen‐Wei Hsu, Jung-Hua Liu, et al.
American Journal of Kidney Diseases (2025)
Open Access | Times Cited: 1
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2019) Vol. 11, Iss. 2, pp. 369-386
Open Access | Times Cited: 59
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
Peter Rossing, Rajiv Agarwal, Stefan D. Anker, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 125-134
Open Access | Times Cited: 51
New Pandemic: Obesity and Associated Nephropathy
Isha Sharma, Yingjun Liao, Xiaoping Zheng, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 42
Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases
Shang‐Der Chen, Yao‐Chung Chuang, Tsu‐Kung Lin, et al.
European Journal of Pharmacology (2022) Vol. 938, pp. 175439-175439
Closed Access | Times Cited: 34
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Mariam M. Ali, Sanober Parveen, Vanessa Williams, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100341-100341
Open Access | Times Cited: 7
Exercise in Diabetic Nephropathy: Protective Effects and Molecular Mechanism
Ruo-Ying Li, Liang Guo
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3605-3605
Open Access | Times Cited: 6
GLP-1 receptor agonists
L. G. Clark
JAAPA (2024) Vol. 37, Iss. 4, pp. 1-4
Closed Access | Times Cited: 6
Targeting Redox Imbalance as an Approach for Diabetic Kidney Disease
Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, et al.
Biomedicines (2020) Vol. 8, Iss. 2, pp. 40-40
Open Access | Times Cited: 43
Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions
Claudio González, María Paula Carro Negueruela, Catalina Nicora Santamarina, et al.
Cells (2021) Vol. 10, Iss. 9, pp. 2497-2497
Open Access | Times Cited: 39
How glucagon-like peptide 1 receptor agonists work
Christine R. Andreasen, Andreas Andersen, Filip K. Knop, et al.
Endocrine Connections (2021) Vol. 10, Iss. 7, pp. R200-R212
Open Access | Times Cited: 34
Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
Maria Mirabelli, Eusebio Chiefari, Vera Tocci, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 5, pp. 985-985
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top